{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:51:53Z","timestamp":1789480313389,"version":"build-2803163510"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81571596"],"award-info":[{"award-number":["81571596"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81601044"],"award-info":[{"award-number":["81601044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81771279"],"award-info":[{"award-number":["81771279"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["2018TS088"],"award-info":[{"award-number":["2018TS088"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GK201701009"],"award-info":[{"award-number":["GK201701009"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GK201603110"],"award-info":[{"award-number":["GK201603110"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neuroinflammation"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Neuromyelitis optica spectrum disorder (NMOSD), an autoimmune astrocytopathic disease associated with the anti-aquaporin-4 (AQP4) antibody, is characterized by extensive necrotic lesions primarily located on the optic nerves and spinal cord. Tanshinone IIA (TSA), an active natural compound extracted from <jats:italic>Salvia miltiorrhiza<\/jats:italic> Bunge, has profound immunosuppressive effects on neutrophils.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>The present study aimed to evaluate the effect of TSA on NMOSD mice and explore the underlying mechanisms. Mice were initially administered TSA (pre-TSA group, <jats:italic>n<\/jats:italic> = 20) or vehicle (vehicle group, <jats:italic>n<\/jats:italic> = 20) every 8\u2009h for 3 days, and then NMOSD model was induced by intracerebral injection of NMOSD-immunoglobulin G (NMO-IgG) and human complement (hC). In addition, post-TSA mice (<jats:italic>n<\/jats:italic> = 10) were administered equal dose of TSA at 8\u2009h and 16\u2009h after model induction. At 24\u2009h after intracerebral injection, histological analysis was performed to assess the inhibitory effects of TSA on astrocyte damage, demyelination, and neuroinflammation in NMOSD mice, and western blotting was conducted to clarify the effect of TSA on the NF-\u03baB and MAPK signaling pathways. Furthermore, flow cytometry and western blotting were conducted to verify the proapoptotic effects of TSA on neutrophils in vitro.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>There was a profound reduction in astrocyte damage and demyelination in the pre-TSA group and post-TSA group. However, prophylactic administration of TSA induced a better effect than therapeutic treatment. The number of infiltrated neutrophils was also decreased in the lesions of NMOSD mice that were pretreated with TSA. We confirmed that prophylactic administration of TSA significantly promoted neutrophil apoptosis in NMOSD lesions in vivo, and this proapoptotic effect was mediated by modulating the caspase pathway in the presence of inflammatory stimuli in vitro. In addition, TSA restricted activation of the NF-\u03baB signaling pathway in vivo.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Our data provide evidence that TSA can act as a prophylactic agent that reduces NMO-IgG-induced damage in the mouse brain by enhancing the resolution of inflammation by inducing neutrophil apoptosis, and TSA may serve as a promising therapeutic agent for neutrophil-associated inflammatory disorders, such as NMOSD.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12974-020-01874-6","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T14:03:43Z","timestamp":1593093823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis"],"prefix":"10.1186","volume":"17","author":[{"given":"Ye","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-ling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan-huan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-chu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao-wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-li","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-li","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang-jun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-2318","authenticated-orcid":false,"given":"Ya-ping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"key":"1874_CR1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","volume":"6","author":"DM Wingerchuk","year":"2007","unstructured":"Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805\u201315.","journal-title":"Lancet Neurol"},{"key":"1874_CR2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","volume":"4","author":"S Jarius","year":"2008","unstructured":"Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol. 2008;4:202\u201314.","journal-title":"Nat Clin Pract Neurol"},{"key":"1874_CR3","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","volume":"66","author":"JL Bennett","year":"2009","unstructured":"Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009;66:617\u201329.","journal-title":"Ann Neurol"},{"key":"1874_CR4","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1136\/jnnp-2016-313300","volume":"88","author":"I Kawachi","year":"2017","unstructured":"Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2017;88:137\u201345.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1874_CR5","first-page":"333","volume":"65","author":"Y Takai","year":"2013","unstructured":"Takai Y, Misu T, Takahashi T, Nakashima I, Fujihara K. NMO spectrum disorders and anti AQP4 antibody. Brain Nerve. 2013;65:333\u201343.","journal-title":"Brain Nerve"},{"key":"1874_CR6","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/brain\/awm062","volume":"130","author":"T Takahashi","year":"2007","unstructured":"Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain. 2007;130:1235\u201343.","journal-title":"Brain"},{"key":"1874_CR7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","volume":"202","author":"VA Lennon","year":"2005","unstructured":"Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005;202:473\u20137.","journal-title":"J Exp Med"},{"key":"1874_CR8","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrneurol.2010.72","volume":"6","author":"S Jarius","year":"2010","unstructured":"Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383\u201392.","journal-title":"Nat Rev Neurol"},{"key":"1874_CR9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1523\/JNEUROSCI.17-01-00171.1997","volume":"17","author":"S Nielsen","year":"1997","unstructured":"Nielsen S, Nagelhus EA, Amiry-Moghaddam M, Bourque C, Agre P, Ottersen OP. Specialized membrane domains for water transport in glial cells: high-resolution immunogold cytochemistry of aquaporin-4 in rat brain. J Neurosci. 1997;17:171\u201380.","journal-title":"J Neurosci"},{"key":"1874_CR10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bpa.12085","volume":"23","author":"AS Verkman","year":"2013","unstructured":"Verkman AS, Phuan PW, Asavapanumas N, Tradtrantip L. Biology of AQP4 and anti-AQP4 antibody: therapeutic implications for NMO. Brain Pathol. 2013;23:684\u201395.","journal-title":"Brain Pathol"},{"key":"1874_CR11","doi-asserted-by":"crossref","unstructured":"Paul F, Jarius S, Aktas O, Bluthner M, Bauer O, Appelhans H, et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 2007;(4):e133.","DOI":"10.1371\/journal.pmed.0040133"},{"key":"1874_CR12","doi-asserted-by":"crossref","first-page":"45156","DOI":"10.1074\/jbc.M111.297275","volume":"286","author":"J Ratelade","year":"2011","unstructured":"Ratelade J, Bennett JL, Verkman AS. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem. 2011;286:45156\u201364.","journal-title":"J Biol Chem"},{"key":"1874_CR13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/ana.21837","volume":"66","author":"M Bradl","year":"2009","unstructured":"Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009;66:630\u201343.","journal-title":"Ann Neurol"},{"key":"1874_CR14","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/glia.20855","volume":"57","author":"GP Nicchia","year":"2009","unstructured":"Nicchia GP, Mastrototaro M, Rossi A, Pisani F, Tortorella C, Ruggieri M, et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia. 2009;57:1363\u201373.","journal-title":"Glia."},{"key":"1874_CR15","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000311","volume":"4","author":"Y Takeshita","year":"2017","unstructured":"Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, Yamamoto E, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm. 2017;4:e311.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1874_CR16","doi-asserted-by":"crossref","first-page":"13829","DOI":"10.1074\/jbc.M112.344325","volume":"287","author":"PW Phuan","year":"2012","unstructured":"Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 protein assembly in orthogonal arrays. J Biol Chem. 2012;287:13829\u201339.","journal-title":"J Biol Chem"},{"key":"1874_CR17","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-013-1128-3","volume":"125","author":"PW Phuan","year":"2013","unstructured":"Phuan PW, Zhang H, Asavapanumas N, Leviten M, Rosenthal A, Tradtrantip L, et al. C1q-targeted monoclonal antibody prevents complement-dependent cytotoxicity and neuropathology in in vitro and mouse models of neuromyelitis optica. Acta Neuropathol. 2013;125:829\u201340.","journal-title":"Acta Neuropathol"},{"key":"1874_CR18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","volume":"126","author":"J Ratelade","year":"2013","unstructured":"Ratelade J, Asavapanumas N, Ritchie AM, Wemlinger S, Bennett JL, Verkman AS. Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica. Acta Neuropathol. 2013;126:699\u2013709.","journal-title":"Acta Neuropathol"},{"key":"1874_CR19","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1172\/JCI67554","volume":"123","author":"H Zhang","year":"2013","unstructured":"Zhang H, Verkman AS. Eosinophil pathogenicity mechanisms and therapeutics in neuromyelitis optica. J Clin Invest. 2013;123:2306\u201316.","journal-title":"J Clin Invest"},{"key":"1874_CR20","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1352458515586084","volume":"22","author":"L Hertwig","year":"2016","unstructured":"Hertwig L, Pache F, Romero-Suarez S, Sturner KH, Borisow N, Behrens J, et al. Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler. 2016;22:160\u201373.","journal-title":"Mult Scler"},{"key":"1874_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ana.22686","volume":"71","author":"S Saadoun","year":"2012","unstructured":"Saadoun S, Waters P, MacDonald C, Bell BA, Vincent A, Verkman AS. Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012;71:323\u201333.","journal-title":"Ann Neurol"},{"key":"1874_CR22","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1177\/1352458512443994","volume":"18","author":"A Jacob","year":"2012","unstructured":"Jacob A, Saadoun S, Kitley J, Leite M, Palace J, Schon F, et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Mult Scler. 2012;18:1801\u20133.","journal-title":"Mult Scler"},{"key":"1874_CR23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","volume":"133","author":"S Saadoun","year":"2010","unstructured":"Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010;133:349\u201361.","journal-title":"Brain."},{"key":"1874_CR24","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.4049\/jimmunol.1600135","volume":"197","author":"K Shi","year":"2016","unstructured":"Shi K, Wang Z, Liu Y, Gong Y, Fu Y, Li S, et al. CFHR1-modified neural stem cells ameliorated brain injury in a mouse model of neuromyelitis optica spectrum disorders. J Immunol. 2016;197:3471\u201380.","journal-title":"J Immunol"},{"key":"1874_CR25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbi.2017.04.023","volume":"65","author":"Z Wang","year":"2017","unstructured":"Wang Z, Guo W, Liu Y, Gong Y, Ding X, Shi K, et al. Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes. Brain Behav Immun. 2017;65:173\u201382.","journal-title":"Brain Behav Immun"},{"key":"1874_CR26","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00401-013-1220-8","volume":"127","author":"C Wrzos","year":"2014","unstructured":"Wrzos C, Winkler A, Metz I, Kayser DM, Thal DR, Wegner C, et al. Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions. Acta Neuropathol. 2014;127:523\u201338.","journal-title":"Acta Neuropathol"},{"key":"1874_CR27","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejphar.2007.04.031","volume":"568","author":"J Fu","year":"2007","unstructured":"Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol. 2007;568:213\u201321.","journal-title":"Eur J Pharmacol"},{"key":"1874_CR28","doi-asserted-by":"crossref","unstructured":"Yu ML, Li SM, Gao X, Li JG, Xu H, Chen KJ. Sodium tanshinone II a sulfonate for coronary heart disease: a systematic review of randomized controlled trials. Chin J Integr Med. 2018.","DOI":"10.1007\/s11655-018-2556-7"},{"key":"1874_CR29","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ijcard.2008.03.020","volume":"135","author":"FF Yan","year":"2009","unstructured":"Yan FF, Liu YF, Liu Y, Zhao YX. Sulfotanshinone sodium injection could decrease fibrinogen level and improve clinical outcomes in patients with unstable angina pectoris. Int J Cardiol. 2009;135:254\u20135.","journal-title":"Int J Cardiol"},{"key":"1874_CR30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12975-017-0526-6","volume":"8","author":"B Ji","year":"2017","unstructured":"Ji B, Zhou F, Han L, Yang J, Fan H, Li S, et al. Sodium tanshinone IIA sulfonate enhances effectiveness Rt-PA treatment in acute ischemic stroke patients associated with ameliorating blood-brain barrier damage. Transl Stroke Res. 2017;8:334\u201340.","journal-title":"Transl Stroke Res"},{"key":"1874_CR31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.3736\/jcim20111109","volume":"9","author":"L Chen","year":"2011","unstructured":"Chen L, Bi XY, Zhu LX, Qiu YQ, Ding SJ, Deng BQ. Flavonoids of puerarin versus tanshinone II a for ischemic stroke: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao. 2011;9:1215\u201320.","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"1874_CR32","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1002\/ptr.2819","volume":"23","author":"G Xu","year":"2009","unstructured":"Xu G, Zhao W, Zhou Z, Zhang R, Zhu W, Liu X. Danshen extracts decrease blood C reactive protein and prevent ischemic stroke recurrence: a controlled pilot study. Phytother Res. 2009;23:1721\u20135.","journal-title":"Phytother Res"},{"key":"1874_CR33","doi-asserted-by":"crossref","first-page":"225ra229","DOI":"10.1126\/scitranslmed.3007672","volume":"6","author":"AL Robertson","year":"2014","unstructured":"Robertson AL, Holmes GR, Bojarczuk AN, Burgon J, Loynes CA, Chimen M, et al. A zebrafish compound screen reveals modulation of neutrophil reverse migration as an anti-inflammatory mechanism. Sci Transl Med. 2014;6:225ra229.","journal-title":"Sci Transl Med"},{"key":"1874_CR34","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cei.12993","volume":"190","author":"S Zhang","year":"2017","unstructured":"Zhang S, Huang G, Yuan K, Zhu Q, Sheng H, Yu R. Tanshinone IIA ameliorates chronic arthritis in mice by modulating neutrophil activities. Clin Exp Immunol. 2017;190:29\u201339.","journal-title":"Clin Exp Immunol"},{"key":"1874_CR35","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.4049\/jimmunol.1701195","volume":"201","author":"Y Sun","year":"2018","unstructured":"Sun Y, Abbondante S, Karmakar M, de Jesus CS, Che C, Hise AG, et al. Neutrophil caspase-11 is required for cleavage of caspase-1 and secretion of IL-1beta in aspergillus fumigatus infection. J Immunol. 2018;201:2767\u201375.","journal-title":"J Immunol"},{"key":"1874_CR36","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.4049\/jimmunol.1701187","volume":"200","author":"EF McNaughton","year":"2018","unstructured":"McNaughton EF, Eustace AD, King S, Sessions RB, Kay A, Farris M, et al. Novel anti-inflammatory peptides based on chemokine-glycosaminoglycan interactions reduce leukocyte migration and disease severity in a model of rheumatoid arthritis. J Immunol. 2018;200:3201\u201317.","journal-title":"J Immunol"},{"key":"1874_CR37","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.intimp.2019.05.023","volume":"73","author":"Z Wang","year":"2019","unstructured":"Wang Z, Li J, Zhang J, Xie X. Sodium tanshinone IIA sulfonate inhibits proliferation, migration, invasion and inflammation in rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol. 2019;73:370\u20138.","journal-title":"Int Immunopharmacol"},{"key":"1874_CR38","volume":"7","author":"X Yin","year":"2012","unstructured":"Yin X, Yin Y, Cao FL, Chen YF, Peng Y, Hou WG, et al. Tanshinone IIA attenuates the inflammatory response and apoptosis after traumatic injury of the spinal cord in adult rats. PLoS One. 2012;7:e38381.","journal-title":"PLoS One"},{"key":"1874_CR39","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1111\/jphp.13087","volume":"71","author":"M Quan","year":"2019","unstructured":"Quan M, Lv Y, Dai Y, Qi B, Fu L, Chen X, et al. Tanshinone IIA protects against lipopolysaccharide-induced lung injury through targeting Sirt1. J Pharm Pharmacol. 2019;71:1142\u201351.","journal-title":"J Pharm Pharmacol"},{"key":"1874_CR40","doi-asserted-by":"crossref","first-page":"6893","DOI":"10.1016\/j.biomaterials.2013.05.021","volume":"34","author":"X Liu","year":"2013","unstructured":"Liu X, Ye M, An C, Pan L, Ji L. The effect of cationic albumin-conjugated PEGylated tanshinone IIA nanoparticles on neuronal signal pathways and neuroprotection in cerebral ischemia. Biomaterials. 2013;34:6893\u2013905.","journal-title":"Biomaterials."},{"key":"1874_CR41","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","volume":"130","author":"SF Roemer","year":"2007","unstructured":"Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007;130:1194\u2013205.","journal-title":"Brain."},{"key":"1874_CR42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jneuroim.2011.03.007","volume":"235","author":"S Saadoun","year":"2011","unstructured":"Saadoun S, Waters P, Macdonald C, Bridges LR, Bell BA, Vincent A, et al. T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. J Neuroimmunol. 2011;235:27\u201332.","journal-title":"J Neuroimmunol"},{"key":"1874_CR43","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/nri957","volume":"2","author":"J Savill","year":"2002","unstructured":"Savill J, Dransfield I, Gregory C, Haslett C. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol. 2002;2:965\u201375.","journal-title":"Nat Rev Immunol"},{"key":"1874_CR44","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd1383","volume":"3","author":"DW Gilroy","year":"2004","unstructured":"Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov. 2004;3:401\u201316.","journal-title":"Nat Rev Drug Discov"},{"key":"1874_CR45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ajh.21078","volume":"83","author":"HR Luo","year":"2008","unstructured":"Luo HR, Loison F. Constitutive neutrophil apoptosis: mechanisms and regulation. Am J Hematol. 2008;83:288\u201395.","journal-title":"Am J Hematol"},{"key":"1874_CR46","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1034\/j.1600-065X.2003.00038.x","volume":"193","author":"HU Simon","year":"2003","unstructured":"Simon HU. Neutrophil apoptosis pathways and their modifications in inflammation. Immunol Rev. 2003;193:101\u201310.","journal-title":"Immunol Rev"},{"key":"1874_CR47","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1100\/tsw.2010.169","volume":"10","author":"D El Kebir","year":"2010","unstructured":"El Kebir D, Filep JG. Role of neutrophil apoptosis in the resolution of inflammation. ScientificWorldJournal. 2010;10:1731\u201348.","journal-title":"ScientificWorldJournal."},{"key":"1874_CR48","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1172\/JCI113970","volume":"83","author":"JS Savill","year":"1989","unstructured":"Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest. 1989;83:865\u201375.","journal-title":"J Clin Invest"},{"key":"1874_CR49","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.4049\/jimmunol.170.2.1027","volume":"170","author":"SA Renshaw","year":"2003","unstructured":"Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, et al. Acceleration of human neutrophil apoptosis by TRAIL. J Immunol. 2003;170:1027\u201333.","journal-title":"J Immunol"},{"key":"1874_CR50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1078\/094471103322004776","volume":"10","author":"BY Lam","year":"2003","unstructured":"Lam BY, Lo AC, Sun X, Luo HW, Chung SK, Sucher NJ. Neuroprotective effects of tanshinones in transient focal cerebral ischemia in mice. Phytomedicine. 2003;10:286\u201391.","journal-title":"Phytomedicine."},{"key":"1874_CR51","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/ana.22657","volume":"71","author":"L Tradtrantip","year":"2012","unstructured":"Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012;71:314\u201322.","journal-title":"Ann Neurol"},{"key":"1874_CR52","volume":"6","author":"W Zhu","year":"2019","unstructured":"Zhu W, Wang Z, Hu S, Gong Y, Liu Y, Song H, et al. Human C5-specific single-chain variable fragment ameliorates brain injury in a model of NMOSD. Neurol Neuroimmunol Neuroinflamm. 2019;6:e561.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1874_CR53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/13543784.2018.1443077","volume":"27","author":"F Paul","year":"2018","unstructured":"Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin Investig Drugs. 2018;27:265\u201371.","journal-title":"Expert Opin Investig Drugs"},{"key":"1874_CR54","volume":"4","author":"SC Hodecker","year":"2017","unstructured":"Hodecker SC, Stellmann JP, Rosenkranz SC, Young K, Holst B, Friese MA, et al. Ruxolitinib treatment in a patient with neuromyelitis optica: a case report. Neurol Neuroimmunol Neuroinflamm. 2017;4:e328.","journal-title":"Neurol Neuroimmunol Neuroinflamm."},{"key":"1874_CR55","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000441","volume":"5","author":"I Katz Sand","year":"2018","unstructured":"Katz Sand I, Fabian MT, Telford R, Kraus TA, Chehade M, Masilamani M, et al. Open-label, add-on trial of cetirizine for neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm. 2018;5:e441.","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neuroinflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12974-020-01874-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12974-020-01874-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T23:20:00Z","timestamp":1624576800000},"score":1,"resource":{"primary":{"URL":"https:\/\/jneuroinflammation.biomedcentral.com\/articles\/10.1186\/s12974-020-01874-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1874"],"URL":"https:\/\/doi.org\/10.1186\/s12974-020-01874-6","relation":{},"ISSN":["1742-2094"],"issn-type":[{"value":"1742-2094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"13 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures were approved by the Committee for Research and Animal Ethics of Shaanxi Normal University and conducted in accordance with the US Public Health Service\u2019s Policy on Human Care and Use of Laboratory Animals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}